Ebola hemorrhagic fever for the first time vaccine development vaccination WHO Nov. 16 4:30
About the Ebola vaccine, WHO has announced that the World Health Organization will meet the standards for safety and efficacy, and that vaccination will be promoted in countries that are at risk of infection. This is the first time that a vaccine has been developed, and experts say that it is highly significant that a countermeasure against Ebola was obtained.
Ebola hemorrhagic fever is transmitted through contact with the patient's blood and body fluids and is a viral infection with a high fatality rate of 25% or more. In the Democratic Republic of the Congo in central Africa, more than 2000 people have died since August last year. , WHO has declared a “public health emergency”.
According to WHO and others, as a result of inoculating about 16,000 people with a virus-attenuated vaccine under development by an American pharmaceutical company, there was no problem with safety and it showed the effect of preventing infection.
In response, European regulatory authorities have approved the vaccine this week and announced that in the future there will be vaccinations in countries that are at risk of infection, assuming that WHO has also met safety and efficacy standards.
This is the first time a vaccine has been developed, and WHO Director Tedros commented that "Ebola hemorrhagic fever is now possible to prevent and treat."
Masayuki Saijo, director of the National Institute of Infectious Diseases Virus, 1st part, says, “It is very significant that the countermeasures have been obtained.